NCT05640245 - Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic Arthritis | Biotech Hunter

Enrollment

207

Participants

Timeline

Start Date

December 13, 2022

Primary Completion Date

September 5, 2023

Study Completion Date

January 15, 2024

Conditions

Arthritis, Psoriatic

Interventions

DRUG

Sonelokimab

randomized treatment; parallel group

DRUG

Placebo

randomized treatment; parallel-group

DRUG

Adalimumab

randomized treatment; parallel-group

Trial Locations (42)

1023

Clinical Site, Budapest

1027

Clinical Site, Budapest

1036

Clinical Site, Budapest

1336

Clinical Site, Sofia

4002

Clinical Site, Plovdiv

4003

Clinical Site, Plovdiv

5800

Clinical Site, Pleven

5803

Clinical Site, Pleven

6000

Clinical Site, Stara Zagora

6600

Clinical Site, Szentes

7002

Clinical Site, Rousse

8000

Clinical Site, Székesfehérvár

8200

Clinical Site, Veszprém

8208

Clinical Site, Sabadell

9000

Clinical Site, Varna

10128

Clinical Site, Tallinn

15702

Clinical Site, Santiago de Compostela

16635

Clinical Site, Duncansville

20095

Clinical Site, Hamburg

20708

Clinical Site, Tartu

28100

Clinical Site, Madrid

41010

Clinical Site, Seville

44649

Clinical Site, Herne

92260

Clinical Site, Rancho Mirage

702 00

Clinical Site, Ostrava

15-077

Clinical Site, Bialystok

15-351

Clinical Site, Bialystok

15-879

Clinical Site, Bialystok

85-065

Clinical Site, Bydgoszcz

85-168

Clinical Site, Bydgoszcz

82-300

Clinical Site, Elblag

81-338

Clinical Site, Gdynia

30-727

Clinical Site, Krakow

90-242

Clinical Site, Lodz

05-830

Clinical Site, Nadarzyn

67-100

Clinical Site, Nowa Sól

10-117

Clinical Site, Olsztyn

61-113

Clinical Site, Poznan

96-500

Clinical Site, Sochaczew

58-100

Clinical Site, Swidnica

02-665

Clinical Site, Warsaw

52-416

Clinical SIte, Wroclaw